DARZALEX® Clinical Studies:

DARZALEX® in combination with Pomalyst® 
(pomalidomide) + dexamethasone

DARZALEX® was studied in combination with Pomalyst®and dexamethasone (Pd) in 103 people who had received a prior proteasome inhibitor (PI) and an immunomodulatory agent. These people had received a median of four prior lines of therapy for their multiple myeloma.

The main goal of the study was to measure overall response rate, which is the percentage of people who responded to treatment.

Clinical trial results: DARZALEX® + Pd vs Pd alone

When these people were treated with DARZALEX® in combination with Pd, 59% responded

  • This response lasted for a median duration of 13.6 months (range: 0.9+ to 14.6+ months).

Of people who responded, response was seen between 0.9 and 2.8 months

13.6 months
Median duration of response

1 month
Median time it took people to respond to DARZALEX®

2.8 months
Maximum time it took people to respond to DARZALEX®